Arterial HypertensionNCT05088486

The Role of Genetic Factors in the Development of Arterial Hypertension in the Kazakh Population

An observational study of Arterial Hypertension, run by Asfendiyarov Kazakh National Medical University at 1 site in Kazakhstan.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record

Search all trials

Trial summary

Who is it for?: Ages 18 to 55 years
Conditions the study is for: Arterial Hypertension
What is being tested?: DNA analysis
How many people: 1,200 participants
Where: 1 siteKazakhstan
Study dates: 30 Mar 2022to 20 Jan 2023
Phase: Observational
Are there results?: None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 18 to 55 years
All sexes
Adult

Study population: patients with arterial hypertension of Kazakh nationality

Who may be able to join

Persons with confirmed arterial hypertension;
The age of patients is from 18 to 55 years old inclusive;
Persons of Kazakh nationality, whose paternal and maternal grandparents identify themselves as Kazakhs;
Persons who are able and willing to provide written informed consent;
Persons capable and willing to comply with the research protocol;

Who cannot join

Persons under 18 and over 55;
Persons who, in the opinion of the researcher, are mentally or legally incapacitated, which prevents obtaining informed consent;
Pregnant or lactating women;
Tuberculosis of any localization in the active phase and in history;
Severe and decompensated diseases of the liver and kidneys, cardiovascular system;
Severe and decompensated course of endocrine diseases;

Show all 9Show fewer

Autoimmune diseases;
Systemic diseases;
Cancer.

Trial locations and contacts

1 site in 1 country.

Kazakhstan1 site

Deputy head of Gerontology Center of Medical Centre Hospital of the President's Affairs Administration of the Republic of Kazakhstan
Almaty

Other trials in Kazakhstan

About this study

Official title: Preventive and Personalized Medicine (2021-2023)

This is a GWAS study that aims to identify possible candidate genes associate to arterial hypertension by exploring single nucleotide polymorphism (SNP) in a group of arterial hypertension, in the Kazakh population. The investigators hypothesize that the careful phenotyping of the subject sand matching with increase the power to find SNP significantly associate with arterial hypertension

Read the detailed description

A genome-wide association study (GWAS) is an approach used in genetics research to associate specific genetic variations with particular diseases. The method involves scanning the genomes from many different people and looking for genetic markers that can be used to predict the presence of a disease. Once such genetic markers are identified, they can be used to understand how genes contribute to the disease and develop better prevention and treatment strategies.

Conditions: Arterial Hypertension
Being tested: DNA analysis
Keywords: GWAS
Medical subject headings: Hypertension

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

DNA analysisGenetic
GWAS

Study groups in NCT05088486
Study group	Role	What they receive
Experimental group:		Patients with arterial hypertension Receives: Genetic: DNA analysis
Control group		Patients without arterial hypertension Receives: Genetic: DNA analysis

What is being measured

The primary outcome is the main question the study is designed to answer.

number of SNPs associated with arterial hypertension
Using GWAS to identify candidate genes associate with arterial hypertension
Measured: 1 year

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

30 Mar 202220 Jan 2023

First posted22 Oct 2021
Study start30 Mar 2022
Primary completion20 Jan 2023
Study completion20 Jan 2023

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Other trials for Arterial HypertensionStudies of the same condition, open and under way.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Observational
Observational model: Other
Time perspective: Prospective
Enrolment: 1,200 participants (actual)

IDs, dates and publications

ClinicalTrials.gov ID: NCT05088486
Sponsor's protocol ID: 1193
Status last verified: Mar 2023
First submitted: 25 Sep 2021
Last updated: 14 Mar 2023
Results posted: No
Data monitoring committee: No
FDA-regulated drug: No
FDA-regulated device: No
Individual data sharing: Undecided

Want to know more?

The sponsor has not listed a contact. The official record may have more details.

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

See locations

Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Recruiting
Trial Phase: Syndemic Adapted Medly Uganda
Mental Health
Not yet recruitingPhase 2/3
An Open-Label Extension Study to Evaluate Inhaled Treprostinil SMI in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)
Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
Enrolling by invitation
Testing Implementation Strategies to Support Clinic Fidelity to an Outpatient Hypertension Bundle
Pregnancy Related, Hypertension

All Arterial Hypertension trials

Study at a glance

From the registry record, last updated by the sponsor on 14 Mar 2023. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: Preventive and Personalized Medicine (2021-2023)
ClinicalTrials.gov ID: NCT05088486
Acronym / sponsor ID: 1193
Conditions: Arterial Hypertension
Keywords: GWAS
Study type: Observational
Recruitment status: Completed
Enrolment: 1,200 participants (actual)
Lead sponsor: Asfendiyarov Kazakh National Medical UniversityUniversity, hospital or other
Study start: 30 Mar 2022 (actual)
Primary completion: 20 Jan 2023 (actual)
Study completion: 20 Jan 2023 (actual)
First posted: 22 Oct 2021 (actual)
Results: Not posted in the source record

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

Detailed description

Study design

Observational model: Other
Time perspective: Prospective
Number of arms: 2

Arm	Type	Receives
Experimental group:	–	Genetic: DNA analysisPatients with arterial hypertension
Control group	–	Genetic: DNA analysisPatients without arterial hypertension

Who may qualify

Ages: 18 to 55 years
Sex: All
Age groups: Adult
Study population: patients with arterial hypertension of Kazakh nationality

Key inclusion criteria (5 listed)

Persons with confirmed arterial hypertension;
The age of patients is from 18 to 55 years old inclusive;
Persons of Kazakh nationality, whose paternal and maternal grandparents identify themselves as Kazakhs;
Persons who are able and willing to provide written informed consent;
Persons capable and willing to comply with the research protocol;

Key exclusion criteria (9 listed)

Persons under 18 and over 55;
Persons who, in the opinion of the researcher, are mentally or legally incapacitated, which prevents obtaining informed consent;
Pregnant or lactating women;
Tuberculosis of any localization in the active phase and in history;
Severe and decompensated diseases of the liver and kidneys, cardiovascular system;

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Interventions

Intervention	Type	Arms
DNA analysisGWAS	Genetic	Control group, Experimental group:

Primary outcome

number of SNPs associated with arterial hypertension
Time frame: 1 year
Using GWAS to identify candidate genes associate with arterial hypertension

Results and safety

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 14 Mar 2023.
Individual participant dataSharing planned: Undecided

Related trials for Arterial Hypertension

Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Recruiting
Trial Phase: Syndemic Adapted Medly Uganda
Mental Health
Not yet recruitingPhase 2/3
An Open-Label Extension Study to Evaluate Inhaled Treprostinil SMI in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)
Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
Enrolling by invitation
Testing Implementation Strategies to Support Clinic Fidelity to an Outpatient Hypertension Bundle
Pregnancy Related, Hypertension

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.

Raushan Karibayeva, Doctor of medical sciences study director

Deputy head of Gerontology Center of Medical Centre Hospital of the President's Affairs Administration of the Republic of Kazakhstan

Tamara Vochshenkova, MBA study chair

Deputy head of Gerontology Center of Medical Centre Hospital of the President's Affairs Administration of the Republic of Kazakhstan

1 site in 1 country: see every site and its status.

Questions about this trial

What is this clinical trial studying?

An observational study of Arterial Hypertension, run by Asfendiyarov Kazakh National Medical University at 1 site in Kazakhstan.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 14 Mar 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Kazakhstan. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

number of SNPs associated with arterial hypertension (time frame: 1 year). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05088486.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Mar 2023.